Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
We aimed to compare the efficacy and safety of nab-paclitaxel plus gemcitabine with nab-Paclitaxel plus gemcitabine. Adults (aged 18–75 years) with an...
Evidence-based benchmarks for use of cancer surgery in high-income countries: a population-based analysis
Surgical treatment was indicated in 58% of newly diagnosed patients with cancer in Australia in 2014 at least once during the course of their treatmen...
Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial
Osteolysis causes recurrent pain and disability after total hip arthroplasty. We investigated the effect of the human monoclonal antibody denosumab on...
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial
The optimal radiotherapy dose for indolent non-Hodgkin lymphoma is uncertain. We aimed to compare 24 Gy in 12 fractions with 4 Gy in two fractions (lo...
Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study
New risk model to assess the benefits of adhering to a healthy lifestyle in individuals with a high genetic risk. The polygenic risk score derived fro...
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
EORTC-62092 is an open-label, randomized, phase 3 study done in 31 research institutions, hospitals, and cancer centers in 13 countries in Europe and...
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
The study assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with advanced tumors. Objective responses were observed in 30 (29%) of...
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
GetUG-AFU 17 was a randomized, open-label, multicentre, phase 3 trial done at 46 French hospitals. 5-year event-free survival was 92% in the adjuvant...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
